About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
IONS - Ionis Pharmaceutical...| Previous Close | $46.85 | Open | $46.18 |
| Volume | 977.5K | Market Cap | 6.545B |
| Yield | Last Dividend |
| Ionis and Akcea win prestigious Prix Gal... | 10/30/20 |
| BOSTON and CARLSBAD, Calif., Oct. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeut... | |
| Ionis Pharmaceuticals, Inc. (NASDAQ:IONS... | 10/22/20 |
| Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Director Joseph Klein III sold 2,889 shares of the company???s stock in a transaction on Tuesday, October 20... | |
| Bulbospinal Muscular Atrophy Drugs Marke... | 10/19/20 |
| Global Bulbospinal Muscular Atrophy Drugs Market is growing at a steady CAGR in the forecast period of 2019-2026. The report contains data of the base... | |
| Atherosclerosis Market Shows Strong Grow... | 10/16/20 |
| Atherosclerosis Market analysis report is a professional yet exhaustive study on the current state for the market. The market study of Atherosclerosis... | |
| Ionis antisense medicine being evaluated... | 10/15/20 |
| CARLSBAD, Calif., Oct. 15, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that... | |
| RNA Therapeutics Market 2020 Analysis, S... | 10/14/20 |
| The winning RNA Therapeutics Market report makes available the current and forthcoming technical and financial details of the industry. Few of the chi... | |
| Ionis' inhaled antisense medicine demons... | 10/13/20 |
| CARLSBAD, Calif., Oct. 13, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that... | |
| Ionis Pharmaceuticals completes acquisit... | 10/12/20 |
| /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the successful completion of its transaction to acquire 100% ownership of A... | |
| Aro Collaboration with Ionis Advances wi... | 10/06/20 |
| PHILADELPHIA--(BUSINESS WIRE)--Aro Biotherapeutics, a biotechnology company focused on developing a new generation of medicines based on its proprieta... | |
| Ionis Chief Scientific Officer Frank Ben... | 10/01/20 |
| CARLSBAD, Calif., Oct. 1, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that ... | |
| Ionis and Genuity Science announce agree... | 10/01/20 |
| BOSTON and CARLSBAD, Calif., Oct. 1, 2020 /PRNewswire/ -- Genuity Science, a genomics and data insights organization and Ionis Pharmaceuticals (NASDAQ... | |
| Ionis treatment for Alexander disease re... | 09/30/20 |
| /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that the U.S. Food and Drug Administ... | |
| Global RNA Interference Market To See As... | 09/30/20 |
| This research report acknowledges the presentation segments of the global market. The market was classified in terms of presentation in the next piece... | |
| AKCEA INVESTOR ALERT By the Former Attor... | 09/04/20 |
| NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (???KSF???) a... | |
| Ionis to present at upcoming virtual inv... | 09/03/20 |
| CARLSBAD, Calif., Sept. 3, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that... | |
| INVESTOR ALERT: Monteverde & Associates ... | 09/01/20 |
| NEW YORK , Sept. 1, 2020 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm hea... | |
| Akcea Therapeutics Rallies After Majorit... | 08/31/20 |
| Akcea Therapeutics Inc (NASDAQ: AKCA ) shares were rallying strongly Monday following a buyout deal. The Ionis, Akcea Deal Terms: Akcea and its majori... | |
| Ionis Pharmaceuticals to hold cardio-ren... | 08/26/20 |
| CARLSBAD, Calif., Aug. 26, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesd... | |
| Earnings Scheduled For August 5, 2020 | 08/05/20 |
| Companies Reporting Before The Bell ??? AmerisourceBergen Inc. (NYSE: ABC ) is expected to report quarterly earnings at $1.56 per share on revenue of ... | |
| Ionis Pharmaceuticals to hold second qua... | 07/22/20 |
| /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, August 5th at 11:30 a.m. Eas... | |
| Ionis Pharmaceuticals (IONS) Reports Q1 ... | 05/06/20 |
| Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 9.09% and -16.90%, respectively, for the quarter ended March 2020. Do the num... | |
| Earnings Preview: Ionis Pharmaceuticals ... | 04/29/20 |
| Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get p... | |
| Zacks.com featured highlights include: I... | 04/22/20 |
| Zacks.com featured highlights include: Ionis Pharmaceuticals, Aphria, Tabula Rasa Healthcare, InterDigital and Huron Consulting Group | |
| Ionis Pharmaceuticals to hold first quar... | 04/22/20 |
| CARLSBAD, Calif., April 22, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednes... | |
| Ionis and partner announce enrollment co... | 04/20/20 |
| CARLSBAD, Calif., April 20, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, today announced ... | |
| Why Ionis Pharmaceuticals (IONS) Stock M... | 04/08/20 |
| Ionis Pharmaceuticals (IONS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well | |
| The Daily Biotech Pulse: Mesoblast To Te... | 03/10/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) A... | |
| Ionis Pharmaceuticals Has a Great Pipeli... | 03/05/20 |
| Citi analyst Joel Beatty began coverage of the stock with a Buy rating. | |
| Ionis Pharmaceuticals (IONS) Q4 Earnings... | 02/26/20 |
| Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 40.66% and 21.72%, respectively, for the quarter ended December 2019. Do the ... | |
| Ionis provides fourth quarter and full y... | 02/26/20 |
| CARLSBAD, Calif., Feb. 26, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the fourth quarter... | |
| Sell rating | 10/13/20 |
| Morgan Stanley maintains Underweight rating and lowers Price Target from $54.00 to $50.00 | |
| Buy rating | 09/01/20 |
| Needham maintains Buy rating and raises Price Target from $89.00 to $91.00 | |
| Buy rating | 09/01/20 |
| SVB Leerink maintains Market Perform rating and raises Price Target from $54.00 to $56.00 | |
| Buy rating | 08/10/20 |
| Citigroup maintains Buy rating and lowers Price Target from $80.00 to $78.00 | |
| Sell rating | 08/06/20 |
| Morgan Stanley maintains Underweight rating and lowers Price Target from $56.00 to $54.00 | |
| Date | 2020-08-05 (BMO) | Est. (EPS/Rev.) | ($0.27)/ 148.87M |
| Actual (EPS/Rev.) | $-0.23/ $146.00 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
